Healthcare & Pharmaceuticals
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules.
Should a private company be allowed to patent isolated human genes? A lawsuit to be heard Friday pits Myriad Genetics of Utah against the American Civil Liberties Union (ACLU). Myriad wants to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer.
NEW DELHI -- The Kerala government has decided to introduce legislation to protect the intellectual property rights of its tribespeople who have been practising traditional nature-based medicine for centuries.
LOS ANGELES, Aug. 25 - The attorney general of California sued 39 drug companies on Thursday, accusing them of bilking the state of hundreds of millions of dollars by overcharging for medicines.
Bayer doesn't just make aspirin--it's a major producer of chemicals and drugs with a dubious corporate record. So how did it get into a partnership with the UN? A German activist tells how and why.
Gilead Sciences Inc., a California based pharmaceutical company, has avoided paying $10 billion in taxes by moving its patents to Ireland. This is despite the fact that one of its most profitable drugs was developed with U.S. taxpayer money, according to a new report from Americans for Tax Fairness.
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.
In a move activists hoped would lead to a flood of affordable AIDS medication to Africa, the pharmaceutical industry dropped its suit Thursday challenging a South African law many say would allow the government to import or produce generic versions of the drugs.
JOHANNESBURG -- A severe shortage of two antiretrovirals (ARVs) produced by leading pharmaceutical Bristol-Myers Squibb in Kenya, could have critical repercussions for patients, says Medecines sans Frontieres (MSF).
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.